Abstract The World Health Organization (WHO) recommends countries introduce new anti-
TB drugs in the treatment of multidrug-resistant tuberculosis. The aim of the study is to …

BACKGROUND: For the first time in almost 50 years, there are new drugs available for the
treatment of tuberculosis (TB), including bedaquiline (BDQ) and delamanid (DLM). The rate …

BACKGROUND: The World Health Organization recommends adding bedaquiline or
delamanid to multidrug-resistant tuberculosis (MDR-TB) regimens for which four effective …

Background Bedaquiline and delamanid have been approved for treatment of multidrug-
resistant (MDR) tuberculosis in the past 5 years. Because of theoretical safety concerns …

Background At a time when programs were struggling to design effective regimens for the
treatment of multidrug-resistant tuberculosis (MDR-TB), the marketing authorization of …

SETTING: The World Health Organization recommended two new drugs, bedaquiline (BDQ)
and delamanid (DLM), for the treatment of multidrug-resistant tuberculosis (MDR-TB) in …

There are limited data on combining delamanid and bedaquiline in drug-resistant
tuberculosis (DR-TB) regimens. Prospective long-term outcome data, including in HIV …

The new drugs delamanid and bedaquiline are increasingly used to treat multidrug-resistant
(MDR-) and extensively drug-resistant tuberculosis (XDR-TB). As evidence is lacking, the …

Two new drugs—bedaquiline and delamanid—have recently been approved by stringent
regulatory authorities to treat multidrug-resistant tuberculosis (TB) and recommended by the …

Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) continue
to be challenging at both the patient and programme level. The World Health Organization …